Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1907608 Target Snapshot

Glutamate NMDA receptor · PROTEIN COMPLEX GROUP · Rattus norvegicus

3,932Compounds
839Assays
22Approved Drugs
4,675.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt P35439. Use UniProt P35439 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P35439 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Glutamate NMDA receptor as ChEMBL target CHEMBL1907608, mapped to UniProt P35439. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Glutamate NMDA receptor
PROTEIN COMPLEX GROUP · Rattus norvegicus
As of 2026-09-13
ChEMBL target ID
CHEMBL1907608
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P35439
Glutamate receptor ionotropic, NMDA 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Glutamate NMDA receptor is the right protein anchor across sources, using UniProt P35439 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelGlutamate receptor ionotropic, NMDA 1
UniProt AccessionP35439
Component TypeProtein
Sequence Length938 aa

Glutamate receptor ionotropic, NMDA 1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Glutamate NMDA receptor, mapped to UniProt P35439. ChEMBL maps the protein component as Glutamate receptor ionotropic, NMDA 1. Sequence length is 938 aa.

Mapped IDP35439
Review nameGlutamate NMDA receptor
OrganismRattus norvegicus
Clinical Profile

Clinical Phase Distribution

22
Approved
9
Phase III
33
Phase II
1
Phase I
1
Phase 0.5
Assay Mix

Activity Type Distribution

IC502,943.0
KI1,663.0
EC5056.0
KD13.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL540084 9.47 IC50 0.34 Preclinical
CHEMBL299281 9.12 IC50 0.75 Preclinical
CHEMBL39881 9.02 Ki 0.96 Preclinical
CHEMBL197208 9.0 Ki 1.0 Preclinical
CHEMBL59894 9.0 IC50 1.0 Preclinical
CHEMBL44793 9.0 IC50 1.0 Clinical
CHEMBL383226 8.96 Ki 1.11 Preclinical
CHEMBL212990 8.96 IC50 1.1 Preclinical
CHEMBL1202362 8.92 Ki 1.2 Preclinical
CHEMBL214758 8.92 IC50 1.2 Preclinical
Distribution

pChEMBL Value Distribution

495
5.0
411
5.5
421
6.0
387
6.5
314
7.0
247
7.5
158
8.0
78
8.5
6
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

ESKETAMINE
CHEMBL395091
Approved 2019
GLYCINE
CHEMBL773
Approved 1982
KETAMINE
CHEMBL742
Approved 1970
DEXTROTHYROXINE
CHEMBL559
Approved 1967
Assay Landscape

Assay Landscape

839
Total Assays
2,537
Tested Compounds
3
Assay Types
Binding — 677 assays, 2,537 compounds
BAO Format Assays Compounds Avg pChEMBL
protein complex format 195 364 6.0
cell membrane format 190 1,145 6.1
assay format 162 634 5.9
tissue-based format 94 290 6.1
cell-based format 18 58 5.8
subcellular format 11 16 5.4
cell-free format 4 30 5.4
organism-based format 3 0
Functional — 161 assays, 246 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 91 122 6.1
tissue-based format 33 16 7.4
cell-based format 23 87 5.8
cell membrane format 10 21 4.7
organism-based format 4 0
ADME — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell membrane format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine